Hims & Hers Health CTO Mohamed Elshenawy Buys Shares

Mohamed Elshenawy, the Chief Technology Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently purchased 282,597 shares of the company. This insider buy took place on June 15, 2026, according to a filing with the SEC. The transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Hims & Hers Health, Inc.

Alongside Elshenawy's purchase, several other insiders were active. On June 17, 2026, Elshenawy sold 30,040 shares at an average price of $31.50 under a planned sale. Irene Becklund, the Principal Accounting Officer, sold 4,490 shares on the same day at the same price, also under a planned sale. Michael Chi, the Chief Operating Officer, sold 14,027 shares at $31.50 on June 17, while Soleil Boughton, the Chief Legal Officer, sold 42,261 shares on June 15 without a specified price.

Other Institutional Activity in Hims & Hers Health

Institutional investors have also been adjusting their positions in Hims & Hers Health. BlackRock, Inc. reduced its holdings by 236,346 shares, leaving it with 26,337,158 shares valued at approximately $546.76 million. Vanguard Portfolio Management LLC initiated a position with 10,183,813 shares worth about $211.42 million. Similarly, Vanguard Capital Management LLC entered with 9,339,711 shares valued at roughly $193.89 million. Morgan Stanley increased its stake by 4,959,856 shares, totaling 8,889,088 shares valued at $184.54 million. State Street Corp added 154,498 shares, leading to a total of 7,460,023 shares worth $154.87 million.

Hims & Hers Health, Inc. Stock Up 10.6%

Shares of Hims & Hers Health (NYSE:HIMS) traded around $31.47. The company has a market capitalization of $7.28 billion and a forward P/E ratio of 35.36. Its stock price has ranged from a 52-week low of $13.74 to a high of $70.43. The 50-day moving average is $26.07, and the 200-day moving average is $33.44. The company has a current ratio of 1.69, a quick ratio of 1.46, and a debt-to-equity ratio of 253.73.

Recent Earnings

In its most recent earnings report, Hims & Hers Health reported revenue of $2.37 billion, reflecting a growth rate of 3.8%. The company, however, is not currently profitable, with a net margin of -0.56% and a return on equity of -2.66%. The next earnings announcement is expected on August 10, 2026.

Analysts Set New Price Targets

Several analysts have maintained their ratings on Hims & Hers Health. On May 26, 2026, B of A Securities kept a 'hold' rating with a $25.00 price target. Truist Securities also maintained a 'hold' rating with a $23.00 target on May 22. JP Morgan and Needham both have 'buy' ratings, with targets of $33.00 and $35.00, respectively. The consensus among 14 analysts is a 'hold' rating, with a mean target price of $26.61.

About Hims & Hers Health

Hims & Hers Health, Inc. is a health and wellness platform that connects consumers to licensed healthcare professionals. Based in San Francisco, the company offers a range of health and wellness products and services, including prescription and non-prescription items, over-the-counter drugs, and personalized care products. It operates in several countries, including the U.S., Canada, and the U.K. Led by CEO Andrew Dudum, the company employs over 2,400 people.

Bottom Line

The recent insider activity at Hims & Hers Health, particularly by CTO Mohamed Elshenawy, highlights ongoing interest in the company's stock. While the company faces profitability challenges, its substantial market presence and diverse product offerings keep it on the radar of investors. As always, insider trades are historical records and may not represent current positions.